FDA warns Boiron that Optique 1 Eye Drops are an unapproved new drug sold with drug claims.
What happened
FDA reviewed Boiron's website and Facebook/Instagram pages in July 2023. FDA found that the sites offered Optique 1 Eye Drops for sale and included claims that the product relieves eye irritation, dry eyes, allergies, and eyestrain. FDA concluded the product is a drug and an unapproved new drug because it is not generally recognized as safe and effective and has no FDA-approved application.
What FDA found
Website and social media claims show Optique 1 Eye Drops are intended to treat eye irritation, allergies, and eyestrain, so FDA treats the product as a drug.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)The eye drops are a 'new drug' because they are not generally recognized as safe and effective for the claimed uses.
FD&C Act section 201(p), 21 U.S.C. 321(p)No FDA-approved application is in effect for Optique 1 Eye Drops, so selling it in interstate commerce violates the FD&C Act.
FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)Labeling the product as homeopathic does not exempt it from drug approval, misbranding, or adulteration requirements.
FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)
What FDA wants
FDA asks Boiron to notify FDA in writing within fifteen working days of receipt of the steps taken to correct the violations and prevent recurrence, with related documentation. If Boiron cannot complete corrective action in that time, it must state the reason and when it will finish.
Who should pay attention
- retailers and online marketplaces selling Boiron eye drops
- consumers using homeopathic eye drops
- companies marketing homeopathic drugs with disease claims
This is a summary. Read the original letter on fda.gov.